14 posts tagged technology transfer from Commercializing Science.
Most tech transfer royalty negotiations anchor on industry averages and gut feel. Here's why that produces bad deals and what to use instead.
A. KovacsMTAs look like administrative paperwork, but buried clauses routinely strip universities and startups of the IP rights they need to commercialize research.
A. KovacsField-of-use restrictions in university license agreements promise focused commercialization but routinely strangle deal value and block better applications from reaching market.
A. KovacsVague IP assignment language in sponsored research agreements creates ownership disputes that kill commercialization deals years after the science is done.
A. KovacsExclusive licenses feel like wins for everyone at signing. Here's why they quietly kill commercialization, and what to structure instead.
A. KovacsOption agreements should de-risk early licensing deals, but most TTOs use them wrong. Here's what's broken and how to fix it.
A. KovacsTRL scores feel objective but are routinely gamed or misread. Here's what's really happening and how to use them honestly.
A. KovacsSponsored research agreements shape IP ownership, licensing rights, and spinout potential before a patent is ever filed. Here's what most researchers miss.
A. KovacsProof-of-concept funding is the missing bridge between lab discovery and licensable technology, here's why most institutions underinvest in it.
A. KovacsMost university licensing deals collapse not because of bad science or bad intent, but because of preventable negotiation failures. Here's what actually goes wrong.
A. KovacsMost industry-university partnerships collapse within two years. Here's why most fail and three proven models that deliver results.
A. KovacsMost university spinouts fail because brilliant researchers become accidental executives without proper transition support.
A. KovacsUniversity TTOs focus on licensing revenue and patent counts instead of startup success and economic impact.
A. Kovacs